Systematic Profiling of Alternative Splicing for Sarcoma Patients Reveals Novel Prognostic Biomarkers Associated with Tumor Microenvironment and Immune Cells

Chuan Hu; Yuanhe Wang; Chuan Liu; Rui Shen; Bo Chen; Kang Sun; Huili Rao; Lin Ye; Jianjun Ye; Shaoqi Tian

doi:10.12659/MSM.924126

19 July 2020 : Database Analysis

Systematic Profiling of Alternative Splicing for Sarcoma Patients Reveals Novel Prognostic Biomarkers Associated with Tumor Microenvironment and Immune Cells

Chuan Hu^1ABCEF*, Yuanhe Wang^1ABC, Chuan Liu^2DEF, Rui Shen^1DE, Bo Chen^3F, Kang Sun^1B, Huili Rao^4C, Lin Ye^3E, Jianjun Ye^3C, Shaoqi Tian^1ABCDEF

DOI: 10.12659/MSM.924126

Med Sci Monit 2020; 26:e924126

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 Prognostic AS events in the SARC cohort. (A) The top 20 significant OS-AS events for 7 splicing types (except ME). (B) The top 20 significant DFS-AS events for 7 splicing types (except ME). SARC – sarcoma; OS – overall survival; ME – mutually exclusive exon; DFS – disease-free survival.

Back to the Article

Systematic Profiling of Alternative Splicing for Sarcoma Patients Reveals Novel Prognostic Biomarkers Associated with Tumor Microenvironment and Immune Cells

Your Privacy